Rapid Medical Donation Programme for Breast Cancer (LEGACY)
Rapid Medical Donation Programme for Breast Cancer to Examine Tumour Heterogeneity
Treatment of breast cancer has traditionally been based on the primary tumour's features in the breast. Only recently, when cancer returns at other sites, has there been an attempt to biopsy the metastatic disease and change treatments accordingly. A 'repeat biopsy' can be technically difficult, painful and, when possible, only represents a small sample of one of many metastases.
Even when one deposit responds to a new treatment, a neighbouring one may continue to grow. There is an urgent need to characterise all deposits, particularly the lethal ones which progress despite all treatments.
This study will enable the comprehensive analysis of the metastatic process and the evolution of the breast cancer through the course of its treatment. Patients who have consented during life to donate their tissues for molecular analysis will provide the means for such an analysis.
Main aims:
- To comprehensively and systematically examine metastatic breast cancer by its detailed exploratory molecular characterization to elucidate the possible inter- and intratumoural heterogeneity between the primary tumour and the majority of metastatic sites.
- To map the natural history of the metastatic breast cancer process
研究概览
地位
条件
研究类型
注册 (预期的)
联系人和位置
学习地点
-
-
-
London、英国、SW3 6JJ
- 招聘中
- Royal Marsden NHS Foundation Trust
-
接触:
- Sally Bennett, RN
- 电话号码:+44 (0)20 7153 5004
- 邮箱:LEGACY-BC@icr.ac.uk
-
-
参与标准
资格标准
适合学习的年龄
接受健康志愿者
有资格学习的性别
取样方法
研究人群
描述
Inclusion Criteria:
- Patients who have completed active treatment (or trials) for metastatic breast cancer.
- Patients referred to either community or the hospital-based palliative care unit from Royal Marsden National Health Service Foundation Trust.
Exclusion Criteria:
- Lack of capacity / inability to give informed consent.
- Diagnosis of alternative cancer within the last 5 years other than resected basal cell skin cancer or cervical intraepithelial neoplasia.
- Patients known to be HIV, Hepatitis B virus or Hepatitis C virus positive on serology .
- Spongiform encephalopathy (known or suspected CJD) .
- Eligibility for or current participation in a clinical trial (excluding palliative care trials)
学习计划
研究是如何设计的?
设计细节
研究衡量的是什么?
主要结果指标
结果测量 |
大体时间 |
|---|---|
|
The acquisition of tumour tissue from multiple metastatic sites.
大体时间:Within 6 hours from the time of death.
|
Within 6 hours from the time of death.
|
合作者和调查者
调查人员
- 首席研究员:Peter A Barry, MB BS、Royal Marsden NHS Foundation Trust
研究记录日期
研究主要日期
学习开始
初级完成 (预期的)
研究完成 (预期的)
研究注册日期
首次提交
首先提交符合 QC 标准的
首次发布 (估计)
研究记录更新
最后更新发布 (估计)
上次提交的符合 QC 标准的更新
最后验证
更多信息
此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.